Pharmaceutical Business in China and Worldwide (July)

1. On July 6, Sino Biopharmaceutical Limited announced that F-star, a wholly-owned subsidiary of invoXPharma, had signed a strategic cooperation and licensing agreement with Takeda. This collaboration will utilize F-star's exclusive full person Fcab and tetravalent mAb ² Platform, research and development of a new generation of multi-specific immunotherapy for cancer patients. According to the terms of the agreement, F-star and Takeda will jointly research and develop a new Fcab domain targeting undisclosed immune oncology targets.

2. On July 7th, Jacobiopharma announced that it had received 150 million yuan of funding from Yizhuang Guotou to support the research and development of projects such as Glecirasib. Glecirasib is a KRASG12C inhibitor developed by Jacobiopharma. Currently, Jacobiopharma has initiated multiple Phase I/II clinical trials of Gliese targeting patients with advanced solid tumors in China, the United States, and Europe.

3. On July 10th, Nanobiotix announced a partnership with Johnson & Johnson, granting them a global license to jointly develop and commercialize the NBTXR3. NBTXR3 is a new, potential first in class anti-tumor drug, composed of functionalized Hafnium(IV) oxide (HfO2) nanoparticles, which is administered by one-time intratumoral injection and activated by radiotherapy.

4. On July 10, BeiGene announced that its indirect wholly-owned subsidiary, BeiGene Switzerland, and Novartis signed relevant agreements to jointly terminate the option agreement, and the termination agreement took effect immediately from the signing date. According to the termination agreement, BeiGene Switzerland has regained all the global rights to develop, produce and commercialize the TIGIT monoclonal antibody Ospirimab.

5. On July 13, Roivant announced that it might sell its candidate drug RVT-3101 for Ulcerative colitis to Roche, with a transaction value of more than US $7 billion. Pfizer announced the establishment of a new company called Vant with Roivant in December last year, focusing on the development and commercialization of RVT-3101. RVT-3101 is a potential first in class drug that exerts therapeutic effects by inhibiting tumor necrosis factor like ligand 1A (TL1A) to suppress inflammation and fibrosis pathways.

6. On July 20th, Lizhu Pharmaceutical announced that it had signed a patent and technology transfer agreement with Shanghai HHT Pharmaceutical (a subsidiary of Huahai Pharmaceutical) to acquire all rights and interests of HHT120 in Greater China for a total transaction amount of up to 86 million yuan. HHT120 is a thrombin inhibitor independently developed by HHT Pharmaceutical, which can block the activation of fibrinogen in the blood coagulation cascade reaction, thereby blocking the formation of blood clots.

7. On July 20th, Biotheus announced an agreement with BioNTech. BioNTech has obtained global exclusive options for a preclinical research phase bispecific antibody and a clinical research phase monoclonal antibody for the treatment of malignant tumors of Biotheus. BioNTech is a next-generation immunotherapy company dedicated to pioneering innovative therapies for cancer and other major diseases.

8. On July 24th, Alnylam announced a strategic agreement with Roche to develop and commercialize Alnylam's Zilebesiran for the treatment of hypertension. Zilebesiran is an RNAi drug that targets the expression of angiotensinogen (AGT) in the liver and is currently in phase II development.

Listing

Hong Kong Stock Exchange

1. On July 11th, KELUN Biotech was officially listed on the Hong Kong Stock Exchange. KELUN Biotech is a biopharmaceutical company dedicated to the research and development, manufacturing, and commercialization of innovative drugs in the fields of oncology, immunology, and other treatments. KELUN Biotech was established in 2016, with its research and development pipeline targeting cancer that is common or difficult to treat worldwide, with 5 of them in the critical trial or new drug launch application (NDA) registration stage.

About  the Author:    

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.